AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05122299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study group
Description: Application of acombination of CoQ10 and collagen hydrogel in the socket after extraction then delayed implant insertion at the site of extraction after three months.
Study NCT04927403 — intervention group
Intervention type: OTHER
Intervention: multimodal integrative naturopathic therapy concept
Description: Use of conventional medicine, naturopathic approaches and complementary medical therapy methods
Study NCT05446571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
Study NCT05446571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
Study NCT06584734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Not exercise
Description: Patients were withdrawn from the exercise they had previously been doing during their hemodiafiltration sessions.
Study NCT06584734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise during hemodiafiltration session
Description: Exercise with cycle ergometers during hemodiafiltration session, intensity was measure with power meters in Watts units.
Study NCT05687110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05687110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo medical imaging scans
Study NCT05687110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novobiocin Sodium
Description: Given PO
Study NCT06470971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 Monoclonal Antibody
Description: Receive anti-PD-L1 monoclonal antibody therapy
Study NCT06470971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD1 Monoclonal Antibody
Description: Receive anti-PD1 monoclonal antibody therapy
Study NCT06470971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06470971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06470971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06470971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06470971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05114213 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: online adaptive MR-guided hypofractionated stereotactic radiotherapy
Study NCT04147065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duration of eradication regimen
Description: 14 day eradication regimen
Study NCT04147065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duration of eradication regimen
Description: 14 day eradication regimen
Study NCT06470971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06470971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV
Study NCT04601194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching and Virtual Provider Program Practice
Description: 4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
Study NCT06367218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid based strategy
Description: Induction and maintenance of anesthesia with opioids
Study NCT04992195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory tests and Montreal Cognitive Assessment
Description: Laboratory tests at baseline and 16 weeks (+/-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+/-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+/-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+/-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.
Study NCT04992195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory tests and Montreal Cognitive Assessment
Description: Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.
Study NCT04527146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMAGINE-PD
Description: The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
Study NCT06367218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid-free strategy
Description: Esketamine was used for induction and maintenance of anesthesia
Study NCT04527146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual genetic counseling
Description: The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the PennChart/EPIC electronic medical record dashboard.
Study NCT05192746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: Exercise Therapy and hot pack This tendon exercise program is very effective if done consistently. There are five steps to the program: warm up, stretching exercise, strengthening exercise, stretching exercise, and heat.
Study NCT05192746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: Shock Master 500 device will be applied once a week for four weeks in total. Each treatment consists of 2000 shocks 3 bar pressure, 20 Hz. Each rESWT session will take about 10 minutes. rESWT application will be performed on the supraspinatus trigger point. In successive treatments, there will be using of an energy density equal to 0.28 mJ/mm2
Study NCT04527146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual genetic counseling
Description: The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the PennChart/EPIC electronic medical record dashboard.
Study NCT04527146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone genetic counseling
Description: The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
Study NCT05192746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high power pain threshold ultrasound
Description: High-power, pain-threshold, ultrasound therapy application (in W/cm2) in continuousmodes, to elicit threshold pain, the ultrasound probe must be kept static on the tendon.~Intensity will be gradually increased to the level of maximum pain the patient could bear. It will be kept at that level for 4 to 5 seconds and then will be reduced to the half-intensitylevel for another 15 seconds. This procedure will be repeated 3 times.High-power,
Study NCT06367218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway; Preserved spontaneous breathing
Description: The patient used a laryngeal mask to maintain spontaneous breathing
Study NCT04510779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
Study NCT06367218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double lumen tracheal tube; Mechanical ventilation
Description: The patient was mechanically ventilated using a double-lumen tracheal catheter
Study NCT05376163 — intervention group
Intervention type: OTHER
Intervention: Survey Study
Description: Headache Disabilty Index (HDI) will be applied.
Study NCT06509295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Hypochlorite as Root Canal Irrigant
Description: Calcium Hypochlorite used as root canal irrigant during chemo-mechanical preparation
Study NCT06509295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hypochlorite as Root Canal Irrigant
Description: Calcium Hypochlorite used as root canal irrigant during chemo-mechanical preparation
Study NCT06583499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainable nutrition education based on the transtheoretical model
Description: Before the intervention begins, the Sustainable Nutrition Behaviour Change Stage Survey will be administered to determine participants' training stage. In addition, the Transtheoretical Model (TTM) Based Sustainable Nutrition Scales will be administered to evaluate the effectiveness of the training programme.~TTM Based Nutrition Training Programme consists of 11 modules developed according to the stages of the model.The methodology and tools used are aligned with the objectives of the training programme.The training modules are offered twice a week, with each session lasting a maximum of 40 minutes and continues for a total of 5 weeks. Participants may attend more than one training session in order to develop behaviours that increase adherence to a sustainable diet. At the end of the training programme, data from the Transtheoretical Model-Based Sustainable Nutrition Behaviour Scale will be collected again and evaluated by comparison with the baseline data set..
Study NCT06216210 — intervention group
Intervention type: DRUG
Intervention: opioid-FREE anesthesia.
Description: They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,
Study NCT06216210 — intervention group
Intervention type: DRUG
Intervention: opioid-CONTAINING anesthesia.
Description: The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
Study NCT06169267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration/biopsy
Study NCT06169267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration/biopsy
Study NCT05917171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: painTRAINER
Description: painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
Study NCT06579690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate solution
Description: Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.
Study NCT06579690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: The comparision group will receive 50 mls of 0.9% Normal Saline
Study NCT06169267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration/biopsy
Study NCT06169267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration/biopsy
Study NCT06579846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline and exercise
Description: Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes.
Study NCT06579846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisinicline
Description: Same intervention as the experimental group without directed exercise prescription
Study NCT06169267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Listen to music
Study NCT06169267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06169267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 330 mg
Description: Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 500 mg
Description: Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 660 mg
Description: Adult and adolescent participants with weight more than or equal to (>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 360 mg
Description: Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 360 mg
Description: Participants with weight >=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 540 mg
Description: Participants with weight >=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Study NCT05114213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC chemotherapy
Description: The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
Study NCT05114213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC chemotherapy
Description: The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine 720 mg
Description: Participants with weight >=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate (Pyramax) 360 mg/120 mg
Description: Participants with weight >=24 to \<45 kg will receive dose of 360/120 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine- artesunate (Pyramax) 540 mg/180 mg
Description: Participants with weight >=45 to \<65 kg will receive 540/180 mg dose of Pyronaridine-artesunate (Pyramax) tablets under fasting condition.
Study NCT05689047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate (Pyramax) 720 mg/240 mg
Description: Participants with weight >=65 kg will receive 720/240 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
Study NCT05362747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss and produce vouchers
Description: Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
Study NCT05324540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool therapy
Description: Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
Study NCT05129488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03)
Description: Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution.EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
Study NCT06241495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
Study NCT06241495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
Study NCT04455958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Given PO
Study NCT04455958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05301088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate Scent
Description: Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group.
Study NCT04455958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04455958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06055855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Two-Needle Arthrocentesis
Description: Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
Study NCT06055855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery-Guided Arthrocentesis
Description: Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
Study NCT05375552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.